NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, … Read more
The Board of Directors of ADDvise Group AB (“ADDvise” and the “Company”) presents preliminary financial information for the fourth quarter of 2024 and has, in connection therewith, decided to update the Company’s long-term financial targets. Furthermore, the Board of Directors has decided to postpone the planned listing transfer to Nasdaq Stockholm’s main market. The work … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Rafarm, a leading pharmaceutical company based in Greece. The order is worth approximately EUR 2.6 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q4 2025. For further information, please … Read more
ADDvise Group’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025. The allocation decision can be appealed up until December 20, 2024. For further information, please contact: Staffan … Read more
ADDvise is exploring the possibility of divesting its subsidiary AB Germa. Germa has shifted its focus primarily towards defense equipment, which falls outside of ADDvise’s core business within life science. ADDvise is therefore evaluating options to find a new owner who can further develop Germa and maximize its full potential within the defense segment. Since … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Orbitworks, a company specialized in advanced technology, based in United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q2 2025. … Read more
The third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment for clinical trials, we showed robust development. Excluding these segments, we saw organic growth of 6% for January−September, reflecting the strength of our business. July–September … Read more
ADDvise Group’s subsidiary MRC Systems has received an order from Medisept. The company is a medical device manufacturer for the healthcare industry based in Oran, Algeria. The order is worth approximately USD 1.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new medical device manufacturing facility with … Read more
ADDvise Group’s subsidiary Germa has received an order from Saab AB (publ). The order has a total value of approximately SEK 32.5 million. The order relates to the delivery of equipment and related components. The deliveries will be separated and are expected to be made during 2025 as agreed between Germa and Saab. Payment will … Read more
The departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate … Read more